Evidence map›Paper›PMID 40861741›Full record

ArticleCureus2025

Management of Isolated Axillary Recurrence in Breast Cancer: Is There a Role for Targeted Axillary Dissection?

Christina M Paluskievicz, Mahtab Vasigh, Piyush Rath, Seoho Lee, Lisa Jacobs, Melissa Camp, Julie Lange, David Euhus, Pam Wright, Bonnie Sun and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christina M PaluskieviczSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Mahtab VasighSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Piyush RathKrieger School of Arts and Sciences, Johns Hopkins University, Baltimore, USA.
Seoho LeeSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Lisa JacobsSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Melissa CampSurgery, Johns Hopkins University School of Medicine, Baltimore, USA.
Julie LangeSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
David EuhusSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Pam WrightSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Bonnie SunSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Hanh-Tam TranSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Maureen O'DonnellSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Olutayo SogunroSurgical Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The most optimal surgical strategy for ipsilateral isolated axillary recurrence (AR) in breast cancer is unknown. Axillary lymph node dissection (ALND) has historically been implemented; however, there may be an evolving role for targeted axillary dissection (TAD). Methods A retrospective analysis was conducted on patients with invasive breast cancer, followed by AR. Clinical and operative strategies were collected, with primary endpoints including overall survival (OS) and progression-free survival (PFS). Results In total, 21 (10.2%) patients were identified with AR. Of this subset of patients, 15 (71.4%) underwent ALND, and six (28.6%) underwent TAD. Univariable and multivariable analyses did not observe a significant association between TAD versus ALND at the time of recurrence with PFS. Univariable analysis demonstrated a significant association between adjuvant radiation and endocrine therapy at first recurrence and PFS benefit. Conclusions Following AR, no PFS benefit was observed between those managed with TAD versus ALND, which highlights an additional area of consideration for possible axillary de-escalation.

Indexed as

axillaaxillary lymph node dissectionbreast cancerisolated axillary recurrencesurvivaltargeted axillary dissection

Identifiers

PMID40861741
PMCPMC12375383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.